E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Dyspepsia (according to the Rome III criteria) with heartburn.
Upper gastro-intestinal causes of the complaints excluded via gastroscopy |
Dyspepsie (volgens de Rome III criteria) met bijkomend zuurbranden.
Gastroscopie reeds gebeurd voor bovenste gastro-intestinale oorzaken uit te sluiten. |
|
E.1.1.1 | Medical condition in easily understood language |
Complaints of heartburn and indigestion. No abnormalities during endoscopy. |
Klachten van zuurbranden en maagklachten. Geen afwijkingen bij endoscopie. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of Iberogast on heartburn, the number of reflux episodes and sensitivity in patients with dyspepsia. |
Het effect nagaan van Iberogast op zuurbranden, het aantal reflux episodes, en de sensitiviteit in patiënten met dyspepsie. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age above 18
• A history of dyspepsia (according to the Rome III criteria) with heartburn
• Upper gastro-intestinal causes of the complaints excluded via gastroscopy with in addition an abdominal echography if found to be necessary by the physician |
- Ouderdom boven 18
- Klachten van dyspepsie (volgens de Rome III criteria) en zuurbranden
- Er is een gastroscopie gebeurd om sommige oorzaken van de klachten uit te sluiten met bijkomend een abdominale echografie indien de arts dit nodig acht. |
|
E.4 | Principal exclusion criteria |
• Surgery of the GI tract other than appendectomy or cholecystectomy
• Use of any medication with a potential effect on gastrointestinal motility, secretion or sensitivity that cannot be stopped for the duration of the study (e.g. proton pump inhibitors, H2-blockers, tricyclic antidepressants …)
• Proton pump inhibitors cannot be stopped for 7 days before start of the study
• Known Barrett’s oesophagus
• History of GI cancer
• Known allergy to one of the ingredients of Iberogast
• Known diabetes
• Severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders)
• Pregnancy (women will be asked if they are pregnant) |
- Chirurgie van het gastrointestinaal stelsel behalve appendectomie of cholecystectomie
- Gebruik van medicatie met een potentieel effect op de gastro-intestinale motiliteit, secretie en/of gevoeligheid die niet kan worden gestopt voor de duur van de studie (bijv. proton pomp inhibitoren, H2-antagonisten, tricyclische antidepressiva...)
- Proton pomp inhibitoren die niet gestopt kunnen worden voor 7 dagen voorafgaand aan het onderzoek
- Gekende Barrett slokdarm
- Voorgeschiedenis van gastro-intestinale kanker
- Gekende allergieën voor één van de ingrediënten van Iberogast
- Gekende diabetes
- Ernstige en klinisch onstabiele, gelijktijdig optredende ziekte (bijv. lever-, hart- of longziekte, neurologische of psychiatrische aandoeningen, kanker of AIDS of andere endocriene aandoeningen)
- Zwangerschap (vrouwen zullen worden gevraagd of ze zwanger zijn) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Gastro-oesophageal reflux disease symptom score improvement based on RDQ Questionnaire score |
GERD symptoom score verbetering gebaseerd op de RDQ questionnaire score |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Week 4 and week 8 |
Week 4 en week 8 |
|
E.5.2 | Secondary end point(s) |
Number of gastro-oesophageal reflux episodes during the 24-hr study (both mixed/liquid reflux episodes and both acidic and non-acidic episodes)
Proportion of acid and non-acid reflux episodes
Total acid exposure time during 24-hour pH-impedance studies
Quality of life (using the Quality of life in Reflux and Dyspepsia QoLRaD Questionnaire)
Oesophageal sensitivity to acid perfusion
Time to symptoms during oesophageal acid exposure
Time to pain during oesophageal acid exposure (if present)
Symptom severity during oesophageal acid exposure (VAS) |
Aantal reflux episodes gedurende de 24 uur meting (beide mixed/vloeibare reflux episodes en ook zure en niet-zure episodes)
Proportie van zuur en niet-zure reflux episodes
Totale zuurexpositie gedurende de 24-uur pH-impedantie studie
Kwaliteit van leven (gebaseerd op de QoLRaD questionnaire)
Slokdarmgevoeligheid voor zuur perfusie
Tijd tot symptomen gedurende zuurperfusie
Tijd tot pijn gedurende zuurperfusie (indien aanwezig)
Symptoom sterkte tijdens zuurperfusie (VAS) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Week 4 and week 8 |
Week 4 en week 8 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |